Beyond the mRNA Hype: Abogen Biosciences Pioneers True Innovation with a Validated Platform and Global-First Pipeline

This article is based on publicly available information and is intended solely for informational purposes; it does not constitute any investment advice.

The mRNA frenzy from 2020 to 2022 still feels like a grand fireworks display in retrospect.

At that time, the world suddenly realized that messenger RNA (mRNA) could be a therapeutic drug—not just a vaccine—but an entirely new paradigm capable of disrupting small molecules, monoclonal antibodies, and even gene therapy. Capital, driven by hope, flooded in, and dozens of mRNA startups emerged across China.

Abogen Biosciences is undoubtedly the most prominent among them: its ARCoV vaccine, developed in collaboration with Walvax Biotechnology, became China’s first mRNA COVID-19 vaccine to enter Phase III clinical trials and receive emergency use authorization abroad. In July 2021, Abogen completed a Series C financing round exceeding $700 million, setting a new record for the largest single private-market funding deal in China’s biotech sector at that time.

Then, the fireworks dispersed.

The COVID-19 pandemic has been declared over, prompting a shift in public health policies worldwide and a precipitous drop in demand for mRNA COVID-19 vaccines. Capital market enthusiasm for the "next mRNA unicorn" has cooled rapidly, with players in the same sector either laying off staff, pivoting their business models, or quietly disappearing.

Rarely noticed by the outside world, Abogen did not stand still during that quiet ebb; it quietly extended its technology platforms—validated during the COVID-19 pandemic—to areas such as herpes zoster, respiratory syncytial virus (RSV), tumor immunotherapy, and even in vivo-encoded T-cell engagers (TCEs).

On June 15, Abogen registered the Phase III clinical trial (CTR20262350) of its lyophilized mRNA vaccine for herpes zoster, ABO1108, on the Drug Clinical Trial Registration and Information Publicity Platform, planning to enroll 18,000 healthy subjects aged 40 years and older.

This is the first mRNA vaccine for herpes zoster worldwide to enter Phase III clinical trials.

01

After the Tide Recedes: From "COVID-19 Speed" to "Platform Depth"

To be fair, the most valuable asset Abogen acquired during the three years of the pandemic was not fame or financing, but a complete mRNA end-to-end technology stack validated through large-scale Phase III clinical trials.

Its core includes:

Proprietary Nucleobase Modification Technology: A nucleoside modification strategy that breaks through overseas patent barriers, analogous to the pseudouridine (Ψ) modification approach of Moderna/BioNTech but with independent intellectual property rights.Proprietary Ionizable Lipid LNP Delivery System: The core components have been validated in Phase III clinical trials involving tens of thousands of participants in China and Indonesia. The system has received patent approvals in China, the United States, Australia, and Europe, representing one of the very few LNP formulations in China that has truly undergone large-scale clinical validation.Lyophilized Formulation Process: Unlike liquid LNP-mRNA vaccines that require storage and transportation at -70°C or -20°C, Abogen’s late-stage COVID-19 vaccine and subsequent pipeline candidates (ABO1105/ABO1108) all adopt lyophilized formulations. These can be stably stored for two years under mild conditions of 2–8°C, offering significant advantages in storage, transportation, accessibility, and convenience.AI-Assisted Sequence Design and UTR Screening Platform: Systematically enhances mRNA stability, translation efficiency, and immunogenicity through codon optimization, UTR combination screening, and antigen structure prediction.

In the post-COVID-19 era, Abogen has horizontally replicated this platform to other preventive vaccines for infectious diseases and therapeutic oncology products, completing its transformation from "reliance on a single blockbuster product" to a "multi-pipeline platform-based biotech."

02

Infectious Disease Pipeline: No Longer Chasing Hotspots, but Addressing Unmet Needs

1. ABO1108, Lyophilized Herpes Zoster mRNA Vaccine (Core Focus)

Herpes Zoster (HZ) is caused by the reactivation of the varicella-zoster virus (VZV) latent in the dorsal root ganglia. In China, the annual incidence rate among individuals aged 50 years and older exceeds 5%, increasing significantly with advancing age and immunocompromised status.

The current gold standard is GlaxoSmithKline’s recombinant subunit vaccine Shingrix (containing VZV gE antigen and AS01B adjuvant), which demonstrates approximately 90%–97% efficacy after two doses. However, it is associated with a high incidence of local and systemic reactions (moderate-to-severe myalgia, fever, and fatigue in approximately 10%–20% of recipients) and requires strict cold-chain storage and transportation at 2–8°C.

Abogen’s ABO1108 selects VZV gE (glycoprotein E) as the target antigen, but employs a proprietary protein structure design platform to optimize specific mutation sites in gE. Subsequently, its in-house mRNA sequence design platform is used for codon optimization and UTR screening, ultimately encoding the structurally optimized gE antigen to induce robust cellular immunity (CD8+ CTLs).

This is precisely the key to controlling VZV reactivation. Preclinical studies have demonstrated that ABO1108 can induce robust humoral immunity (anti-gE IgG antibodies) and cellular immunity (gE-specific T-cell responses) in animal models, exhibiting favorable immunogenicity.

Key Development Milestones:

March 2025: ABO1108 received implied approval for Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) (acceptance numbers including CXSL2500001); May 2025: Phase I clinical trial was initiated in Guangxi (CTR20251835), enrolling healthy adults to assess safety and immunogenicity; November 2025: Phase II clinical trial was launched (CTR20254264) in individuals aged 40 years and older, with two doses administered approximately 60 days apart. The primary endpoints were anti-gE antibody levels and gE-specific T-cell responses at 14 and 30 days after the second dose; June 2026: A randomized, double-blind, placebo-controlled Phase III clinical trial was officially registered on the platform. The trial aims to enroll 18,000 healthy individuals aged ≥40 years across China, who will receive two intramuscular injections of 0.5 mL reconstituted lyophilized formulation at a 60-day interval. The control group will receive physiological saline placebo. Led by Chief Physician Huang Teng from the Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention (principal investigator), the trial is jointly implemented by the Centers for Disease Control and Prevention of Zhejiang Province, Hebei Province, and Shandong Province.

If AB01108 is ultimately confirmed to be non-inferior or superior to recombinant subunit vaccines, with milder local reactions, it may establish a differentiated advantage in elderly and immunocompromised populations by leveraging the convenience of lyophilized storage and transport at 2–8°C combined with its strong ability to induce cellular immunity. More importantly, as the first herpes zoster mRNA vaccine globally to enter Phase III clinical trials, this “first” signifies that Chinese companies have transitioned from followers to peers, and even leaders, in the field of mRNA preventive vaccines.

2. ABO1105, Lyophilized RSV mRNA Vaccine

Respiratory syncytial virus is a major pathogen causing lower respiratory tract infections in infants, young children, and the elderly. GSK’s Arexvy and Pfizer’s Abrysvo have been marketed globally but have not yet been approved in China.

ABO1105 targets the prefusion conformation of the RSV F protein and utilizes the same lyophilized LNP-mRNA platform. Phase I trials were initiated in May 2025 (CTR20251834), and Phase II trials were publicly registered in September 2025 (CTR20253567); development is currently ongoing.

3. ARCoV Series: The Next-Generation Iteration of COVID-19 mRNA Vaccines

The prototype ARCoV (ARCoV-001) received Emergency Use Authorization (EUA) in Indonesia in 2022, becoming the first Chinese mRNA vaccine approved overseas. Subsequent iterations include the bivalent version ABO1020 targeting Omicron BA.4/5 and the multi-antigen tuberculosis mRNA vaccine (ABO1022), both currently in the preclinical stage.

Although the COVID-19 pipeline is no longer the core focus, the consistency of LNP batches accumulated during Phase III clinical trials, scaled-up GMP manufacturing capabilities (at the Suzhou facility), and regulatory communication experience constitute the foundation for the platform’s broader expansion.

03

Tumor Immunotherapy: The mRNA Journey from "Prevention" to "Treatment"

Abogen’s tumor immunology pipeline focuses on three main lines: therapeutic cancer vaccines (neoantigen/KRAS multi-epitope), in situ in vivo-encoded TCEs (in vivo CAR/TCE), and IL-12 mRNA as monotherapy or in combination.

1. ABO2102, a multi-KRAS mutant mRNA cancer vaccine

KRAS is the most common oncogene in solid tumors (with KRAS mutations present in approximately 30% of non-small cell lung cancers, 40% of colorectal cancers, and 85% of pancreatic cancers). Among these, the G12C mutation accounts for only about 12%, while the remaining "non-G12C" mutations have long lacked targeted therapeutic options.

ABO2102 simultaneously encodes five of the most common KRAS mutant epitopes (covering approximately 75%–85% of patients with KRAS mutations). Following LNP delivery, intracellular translation and presentation via MHC class I and II molecules activate both CD8+ cytotoxic T cells and CD4+ helper T cells, inducing durable immune memory. Preclinical studies demonstrate a synergistic antitumor effect when combined with anti-PD-1 monoclonal antibodies.

In May 2025, it received FDA IND approval (and obtained implicit clinical trial approval in China in August). In December 2025, Phase I trials were initiated in China (CTR20255113), enrolling patients with locally advanced or metastatic solid tumors harboring KRAS mutations, to evaluate the safety, recommended Phase 2 dose (RP2D), and preliminary efficacy of the monotherapy and its combination with sintilimab. It is the first therapeutic mRNA cancer vaccine targeting multiple KRAS mutations to enter clinical trials in China.

2. ABO2011, IL-12 mRNA Tumor Vaccine/Immunomodulator

ABO2011—A lipid nanoparticle injection encoding cytokine IL-12 mRNA, which locally expresses IL-12 in the tumor microenvironment after intratumoral or intravenous administration, activates NK and T cells, and reverses immunologically cold tumors. Currently undergoing Phase I/II clinical trials in China, it is used as monotherapy or in combination with toripalimab (a PD-1 monoclonal antibody) for the treatment of advanced solid tumors (including third-line and beyond for nasopharyngeal carcinoma).

3. ABO2203, an in vivo-encoded CD3×CD19 TCE

This is one of Abogen’s more forward-looking pipelines: LNP-encapsulated mRNA translates in vivo into a bispecific T-cell engager (TCE) targeting CD3 and CD19, thereby avoiding the complex purification processes and peripheral off-target toxicity associated with traditional recombinant TCEs.

Preclinical B-NHL models demonstrated overall response rates (ORR) of 33%, 67%, and 100% in the low-, medium-, and high-dose groups, respectively. Complete metabolic response was observed in the medium- and high-dose groups, with no discontinuations due to adverse events (AEs). Currently in the early clinical/Pre-IND stage, successful development would mark a landmark product in the field of “in vivo biologics manufacturing.”

4. ABOR2013, Personalized Neoantigen Vaccine

ABOR2013 is the world’s first novel neoantigen mRNA vaccine for lung cancer. In April 2023, the First Affiliated Hospital of Guangzhou Medical University (Guangzhou Institute of Respiratory Health) spearheaded the official launch of an investigator-initiated trial (IIT) to evaluate the safety, tolerability, and efficacy of ABOR2013 as monotherapy or in combination with the anti-PD-1 monoclonal antibody sintilimab in patients with lung cancer.

This vaccine targets EGFR mutation-positive non-small cell lung cancer (NSCLC) and can effectively stimulate patients' T-cell immune responses and tumor cell-killing effects. Compared with traditional protein- or peptide-based cancer vaccines, mRNA vaccines are not influenced by patients' HLA haplotypes, allowing the use of engineering strategies to enhance stability while maintaining immunogenicity.

5. ABOR2014 (IPM511), the world’s first mRNA vaccine encoding nearly 20 liver cancer antigens

On November 17, 2023, Zhenzhi Medicine and Abogen jointly announced that the first tumor antigen mRNA therapeutic vaccine, ABOR2014 (IPM511), had completed its first administration in humans. The study was initiated at Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences. It aims to evaluate the safety, tolerability, and preliminary efficacy of ABOR2014 as a monotherapy and in combination with PD-1 inhibitors for the treatment of advanced hepatocellular carcinoma that has progressed after first-line standard therapy.

ABOR2014 is developed based on Zhenzhi Medical’s innovative IMMURITHMS® tumor antigen epitope computation platform, leveraging Abogen’s proprietary mRNA technology platform for mRNA design and its lipid nanoparticle (LNP) delivery system. It encodes nearly 20 high-frequency antigenic epitopes associated with liver cancer, targeting advanced hepatocellular carcinoma (HCC). Upon intramuscular injection, it induces the patient’s own immune system to restore anti-tumor capabilities. Preclinical studies have demonstrated robust antigen presentation, displaying tumor antigens on both MHC class I and MHC class II molecules, and exhibiting the ability to activate specific CD8+ and CD4+ T cells along with significant anti-tumor activity.

04

Why ABO1108 Deserves a Separate Write-up

Among all pipeline candidates, ABO1108 carries not only commercial expectations but also serves, in a sense, as a direct answer to the question of whether Chinese mRNA companies can develop world-class products.

The shingles vaccine market has long been monopolized by GSK’s Shingrix, but its adjuvant system is complex, supply has occasionally been tight, and some elderly individuals hesitate to get vaccinated due to side effects. The mRNA approach can theoretically induce a stronger CD8+ T-cell response with lower doses (control of VZV relies on cellular immunity), and lyophilized formulations eliminate the need for ultra-cold chain logistics.

Abogen leveraged its LNP and lyophilization processes, refined during the COVID-19 pandemic, to undertake this initiative. This was not a simple matter of "swapping out the antigen," but rather the most comprehensive review of the platform capabilities accumulated over the past three years.

Phase I/II data demonstrated favorable immunogenicity and safety signals (specific values were not fully disclosed by the company but were sufficient to support the Phase III decision). The Phase III trial, enrolling 18,000 participants, was designed in accordance with international mainstream standards for confirmatory vaccine trials, with primary endpoints of protective efficacy (comparison of case counts against placebo) and safety.

Upon success, ABO1108 will not only be the first domestically developed mRNA non-COVID-19 vaccine to be marketed in China, but also the first mRNA vaccine for herpes zoster to be approved globally.

This Phase III registration in June 2026 marks exactly seven years since the first synthesis of the COVID-19 spike protein mRNA at Abogen’s BioBAY laboratory in Suzhou.

05

Epilogue

Six and a half years ago, Abogen Biosciences synthesized the mRNA encoding the SARS-CoV-2 spike protein for the first time in its laboratory at Suzhou BioBAY. At that time, mRNA was neither a competitive track nor a trending hotspot; it was merely a direction believed in by a select few.

Today, it holds in its portfolio China’s only self-developed LNP platform validated through large-scale Phase III trials, the world’s first mRNA vaccine for herpes zoster to enter Phase III clinical trials, a KRAS-targeted cancer vaccine filed for regulatory approval in both China and the United States, and an early-stage yet clearly directed pipeline of in vivo-encoded TCE therapeutics. As the tide of the COVID-19 pandemic recedes, this company has remained firmly on shore.

No one can predict in advance whether these pipelines will ultimately succeed. But one thing is certain: companies willing to spend seven years building a technology platform from scratch, expanding it into four therapeutic areas, and advancing it to Phase III clinical trials are inherently rare during the long ramp-up period of innovative drug development in China.

Scarcity does not necessarily mean success, but success often grows out of scarcity.

       Original Title: In-Depth Analysis of Abogen: True Innovation Has Only Just Begun After the mRNA Wave Subsides